Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Efficacy was based on the MRD-negative CR rate at the end of induction.
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
The efficacy of inotuzumab ozogamicin was assessed in a multicenter, single-arm, open-label study in 53 pediatric patients.
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
Advertisement
Most patients in the lower-dose group achieved complete remission or complete remission with partial hematologic recovery.
The percentage of KMT2A-altered cells decreased from 59.2% to 8.1% after treatment with JNJ-75276617.
53.8% of patients treated with blinatumomab achieved MRD negativity within a median of 3.1 months, as detected with clonoSEQ.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia.
The approval is based on the clinical results from a single-arm, multicenter, pivotal study in China.
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
93% of patients became measurable residual disease (MRD) negative after the first cycle of blinatumomab.
Adding blinatumomab to consolidation chemotherapy represents a new standard of care in newly diagnosed B-lineage ALL.
After a follow-up of 24 months, the two-year relapse free survival was 54% and the two-year overall survival rate was 60%.
The effect of elevated BMI was more pronounced in older adolescent and young adults (AYAs) compared to younger AYAs.
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
The strategy is “potentially translatable to all T-cell derived hematological malignancies," according to researchers.
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.